ACTU — Actuate Therapeutics Inc

Actuate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$59.0M

P/E Ratio

-2.60

Beta

0.12

52-Week Range

2.051-11.99

Dividend Yield

$0.00

CEO

Daniel Schmitt

Employees

10

IPO Date

Aug 13, 2024

Exchange

NASDAQ